Immunic (IMUX) Capital Expenditures (2013 - 2026)

Immunic has reported Capital Expenditures for 14 years, with the latest figure at $2000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 95.74% year-over-year to $2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116000.0 (down 58.57% YoY) and the FY2025 annual result came in at $161000.0, down 39.02% from the prior year.
• Capital Expenditures fell to $2000.0 in Q1 2026 per IMUX's latest filing, from $11000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $180000.0 in Q2 2024 and troughed at -$1000.0 in Q4 2022.
• A 5-year average of $51352.9 and a median of $36000.0 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures sank 105.26% in 2022, then jumped 16600.0% in 2023.
• Over 5 years, Capital Expenditures stood at -$1000.0 in 2022, then surged by 16600.0% to $165000.0 in 2023, then plunged by 98.18% to $3000.0 in 2024, then surged by 266.67% to $11000.0 in 2025, then slumped by 81.82% to $2000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $2000.0, $11000.0, and $67000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.